FDA approves Taro Pharmaceutical Industries' Fluorouracil Topical Cream ANDA

Taro Pharmaceutical Industries Ltd. (“Taro” or the “Company,” Pink Sheets: TAROF) today reported that it received approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (“ANDA”) for Fluorouracil Topical Cream USP, 5% (“fluorouracil cream”).

Taro’s fluorouracil cream is a prescription pharmaceutical product used for topical treatment of multiple actinic or solar keratoses and superficial basal cell carcinomas, and is bioequivalent to Efudex® Topical Cream 5% of Valeant Pharmaceuticals International. According to industry sources, Efudex® Topical Cream 5% had annual U.S. sales in 2009 of approximately $70 million.

Source:

Taro Pharmaceutical Industries Ltd.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
DNA sequencing of residual disease accurately identifies leukemia patients who would relapse